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Abstract
Objective—To establish whether the analysis of whole blood gene expression can be useful in
predicting or monitoring response to anti-TNF therapy in RA.
Methods—Whole blood RNA (PAXgene) was obtained at baseline and 14 weeks on three
independent cohorts with a combined total of 250 patients with rheumatoid arthritis beginning
anti-TNF therapy. We employed an approach to gene expression analysis that is based on gene
expression “modules”.
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Results—Good and Moderate Responders by EULAR criteria exhibited highly significant and
consistent changes in multiple gene expression modules using a hyper geometric analysis after 14
weeks of therapy. Strikingly, non responders exhibited very little change in any modules, despite
exposure to TNF blockade. These patterns of change were highly consistent across all three
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cohorts, indicating that immunological changes after TNF treatment are specific to the
combination of both drug exposure and responder status. In contrast, modular patterns of gene
expression did not exhibit consistent differences between responders and non-responders at
baseline in the three cohorts.
Conclusions—These data provide evidence that using gene expression modules related to
inflammatory disease may provide a valuable method for objective monitoring of the response of
RA patients who are treated with TNF inhibitors.

INTRODUCTION

Author Manuscript
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The development of TNF inhibitors for the treatment of rheumatoid arthritis and other
inflammatory disorders has been a seminal advance for the field of rheumatology(1).
However, therapeutic approaches to RA remain a substantial clinical challenge, since
approximately 30% of RA patients do not respond to TNF blockade, and many others obtain
only partial reduction in joint inflammation(2). In addition, the determination of the clinical
response to drug therapy is an inexact science, largely relying on both subjective perceptions
of patients as well as physician assessments of disease activity which exhibit considerable
variability. The integration of laboratory measures of inflammatory activity such as the CRP
or the ESR is standard, but non-specific, and these measurements often do not follow the
clinical parameters(3). The recent development of multi-parameter methods to determine
disease activity may be helpful (4-5), but these biomarkers have not yet been widely used in
formal studies of clinical drug response or demonstrated to benefit patient management.
Thus, there is a substantial unmet need for improvement in both prediction of drug response
in order to individualize therapy, as well as in the development of quantitative laboratory
methods to determine clinical activity of disease, which in turn will aid in the development
of predictive biomarkers and enable more precise treatment concepts such as “treat to target”
(6)
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Expression microarrays have been utilized by a number of groups in order to develop
biomarkers for drug response(7-15). However, the early applications of this technology have
been compromised by a number of issues(16). First, small sample sizes for initial feature set
definition lead to over-fitting of discriminative models and is further compromised by the
semi-quantitative nature of disease activity phenotypes. Critically, there has been rather
limited replication of specific predictive gene expression patterns between studies conducted
to date. Although transcriptomics is a maturing technology, there are various approaches to
expression analysis and sample collection methods are often not standardized. Many studies
examine gene expression in purified peripheral blood mononuclear cells. This can lead to
experimental noise due extracorporeal changes in gene expression, especially if RNA
purification is not carried out immediately. More recently, the use of PaxGene or other
technologies which stabilize whole blood RNA in the collection tube has helped to reduce
this source of variability. Of course, this does not permit the analysis of expression in
specific separated cell subsets of interest. Overall, none of these studies have provided
convincing, replicated results using a standardized protocol for sample collection,
microarray platform, and method of analysis(16).
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In the current study we have attempted to address these issues by examining peripheral
blood gene expression using a standard approach to blood sample collection (PaxGene) and
the use of standard Illumina array platforms in three independent, prospectively collected
cohorts of RA patients beginning therapy with TNF inhibitors. In addition, for our primary
approach to analysis, we have taken advantage of an empirically derived set of “modules” of
gene expression developed by Chaussabel and colleagues(17-18). The results reveal that
patients who have a clinical response to TNF inhibition exhibit a common pattern of
changes in these gene expression modules after14 weeks of therapy, whereas clinical nonresponders do not have major changes in modular gene expression. In contrast, we were not
able to identify modular gene expression changes at baseline that identify patients who will,
or will not, respond to TNF blockade. These results suggest to us that global gene expression
patterns in peripheral blood can be a useful adjunct for determining whether clinical
response has occurred. However, we expect that successful prediction of response to therapy
is likely to require a focus on particular cell subsets along with the integration of genetic
factors and additional biomarker data.

PATIENTS AND METHODS
Patient Cohorts
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Three prospectively collected cohorts of patients with rheumatoid arthritis were studied, as
summarized in Table 1. The ABCoN cohort was enrolled as part of the Autoimmune
Biomarkers Collaborative Network, a NIAMS supported contract to develop new
approaches to biomarkers for rheumatoid arthritis and lupus. Fifty (50) ABCoN patients had
complete data available for study. Patients were treated with Enbrel (n=22), Remicade (n
=19), Humira (n=9). At 14 weeks, the following distribution of EULAR responses were
observed: Good Responder=14, Moderate Responder=21, Non-responder=15. A second
patient cohort was taken from GO-FURTHER, a phase III clinical trial of Golimumab (19).
All patients were started on 2 mg/kg IV and clinical assessment of response was determined
at 14 weeks and 72 patients had gene expression data available for analysis. Of these,
EULAR responses were as follows: Good Responder=29, Moderate Responder=37, Nonresponder=6. A third patient cohort of 120 RA patients was taken from a multicenter cohort,
BATTER-UP (BIOMARKERS OF ANTI- TNF-α THERAPY EFFICACY IN
RHEUMATOID ARTHRITIS TO DEFINE UNRESPONSIVE PATIENTS). These patients
were treated with a variety of anti-TNF agents including Enbrel (n=32), Remicade (n=23),
Humira (n=41), CIMZIA (n=14), SIMPONI (n=9). EULAR response rates for the
BATTER-UP cohort were as follows: Good Responder=42, Moderate Responder=39, Nonresponder=39.
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Microarray analysis
All subjects had PaxGene tubes drawn at baseline before starting therapy, and again at 14
weeks. RNA was isolated using Qiagen's QIAcube (Qiagen, Venlo, The Netherlands),
following the manufacturer's protocol for Paxgene Blood RNA part 1, automated protocol.
Extracted samples were eluted in 80ul of elution buffer (BR5), and subsequently run on
Agilent's 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), for integrity, using the
RNA 6000 Nano Chip. Samples with RNA Integrity Numbers (RINs) greater than 6.5 were
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diluted to 30ng/ul in a total 11ul of RNAse free water. Samples were amplified using Life
Technology's Illumina RNA Total Prep Amplification Kit (Life Technologies, Carlsbad,
CA). 750ng of cRNA wasresuspended in 5ul of RNAse-free water for analysis the on the
Human HT-12v4 chip and 1.2ug was resuspended in 10ul for analysis on the WG6v3 Bead
Chip (Illumina, Inc., San Diego, CA). All samples were processed according to the
manufacturer's instructions. The Illumina WG6v3 was utilized for samples in the ABCoN
cohort, while the HT12v4 was used for samples in the GO-FURTHER and BATTER-UP
cohorts.
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Raw data were exported from GenomeStudio and further analyzed with the R programming
language. All 3 data sets were background corrected using the R/Bioconductor package
‘lumi’(20). Data were further transformed using a vst (variance stabilization transformation)
and quantile normalized. The moderated t-statistic from the R/Bioconductor package
‘limma’ (21) was used for differential expression analysis. We analyzed modules of coexpressed genes that have previously demonstrated coordinated regulation of expression
across a set of diseases (whole blood) as described by Chaussabel et al(17). A total of 28
modules were analyzed, each containing 22-325 gene probes. Because modules were
originally defined using Afffymetrix probesets, these probes were mapped to Entrez Gene
ID which in turn were mapped to Illumina probes as shown in Figure 1. Group comparisons
(e.g. modular expression at baseline vs 14 weeks; responders vs.non responders) were
carried out using a moderated t statistic comparing groups and categorizing all individual
probes as up or down regulated using a significance cutoff p<0.05. For each module, we
compiled the list of all significantly changed probes (up or down) at the cutoff significance
P<0.05. We then determined what fraction of the probes are significantly up or down
regulated within a given module. When comparing groups (e.g. responders vs. non
responders) the significance of the observed difference in distribution of up/down regulated
probes in a module was calculated using a hypergeometric test (equivalent to a 2×2 table
analysis by Fischer's exact test).

Author Manuscript

RESULTS
Consistent changes in modular gene expression are observed after 14 weeks of anti-TNF
therapy in clinical responders

Author Manuscript

As originally reported by Chaussabel, 28 gene expression modules can be observed in whole
blood across a variety of inflammatory and infectious diseases(17). Where possible, these
modules were labeled after the fact according to the identity of the gene transcripts present
in these modules (e.g. B cells, myeloid lineage, T cells, Interferon Inducible etc.). However,
many modules could not be easily categorized, and were designated as “Undetermined”. We
have utilized these designations as well as the original module numbers (M1.1-1.8;
M2.1-2.10; M3.1-3.9) in our discussion here.
We initiated analysis by investigating whether changes in modular gene expression occurred
after TNF blockade, and whether these changes differ among responders and non responders
at the 14 week time point. The results for the three datasets are summarized separately for
EULAR Responders (Good and Moderate Responders combined) and EULAR Nonresponders in Figure 2. For each module, the direction of change in module expression is
Arthritis Rheumatol. Author manuscript; available in PMC 2016 February 01.
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shown for each dataset, with statistical significance indicated by the shading of the bars. The
fraction of probes that are significantly changed (up or down) within each module is
indicated by the height of the bars. Note that for the Responder groups, there is a consistent
and statistically significant increase in modules containing transcripts related to plasma cells
(M 1.1), B cells M1.3, MHC and ribosomal proteins (M 1.7), and T cells (M2.8), as well as
a variety of “Undetermined” modules (M1.8, M3.4, M3.7, M3.8, M3.9). In addition, there is
a consistent down modulation of transcripts in several myeloid lineage modules (M1.5,
M2.6) and platelets (M2.1) as well as Inflammation 1 (M3.2) and Inflammation 2 (M3.3).
These results stand in marked contrast to the lack of any consistent modular changes across
the three datasets for nonresponders. Indeed, in general, non responders show a very small
fraction of probes significantly changing when comparing 14 weeks to baseline within any
of the 28 modules.
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In order to provide a more detailed representation of these modular changes and their
magnitude, we have plotted the fold changes for all probes achieving a significant difference
(p<0.05, moderated t-test) within each module, for each dataset and responder group. This is
shown in figure 3A, 3B and 3C for the ABCoN, GO-FURTHER and BATTERUP cohorts,
respectively. Within the responders from the three datasets, there is striking consistency in
the pattern of changes in modules. Significant changes (p<0.005, hypergeometric test) in
probe distribution, up or down, are indicated in red and blue respectively. Indeed, some of
these changes achieve remarkably compelling levels of statistical significance. For example,
the p values associated with reduction in myeloid modules 1.5 and 2.6 after TNF blockade
range from 10-20 to 10-87, and reductions in the “Undetermined” modules 3.2 and 3.3 range
from 10-12 to 10-85 across the various datasets. These dramatic changes are only seen in the
Responder group, with minimal change in patients who are non responders.
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Modules do not exhibit consistent differences between responders and non-responders at
baseline
While substantial changes in modular gene expression are seen in responders after TNF
blockade, the baseline pattern of module expression does not show consistent differences
among the three cohorts (Figure 4). While some of the datasets suggest presence of
meaningful differences between responders and non responders at baseline in one cohort
(for example several “undetermined” modules are relatively less prominent in responders in
the ABCoN cohort), these changes are not replicated in the other two datasets. This
emphasizes the importance of having replication data sets to validate initial findings, and
also demonstrates that an improved understanding of RA patient heterogeneity will be
required for the development of an accurate predictor of drug response.
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DISCUSSION
In this report we have demonstrated a consistent change in whole blood gene expression in
clinically responding RA patients after exposure to TNF blocking agents for 14 weeks.
These changes are not observed in subjects who do not exhibit a clinical response to
treatment, using standard EULAR criteria. The data are based on a consideration of sets of
genes that are expressed together in a modular fashion across different inflammatory
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conditions, as first demonstrated by Chaussabel(17). These data provide compelling
evidence that these gene expression changes are not simply a result of exposure to TNF
blockade, but rather reflect a change in the both the immunological and disease state in
subjects who are responding to TNF therapy. Interestingly, we have recently had an
opportunity to examine a small number of subjects who did not receive study drug (placebo
group: 7 responders, 16 non-responders). In this case, there was no difference between
responders and non responders (data not shown), suggesting that these changes are specific
to physiological effects of drug therapy in the setting of response. However, a larger study
will be required to confirm these findings.
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In contrast to the gene expression changes observed in responders over time, these modules
do not predict response to future response to TNF blockade when these modular expression
patterns are interrogated at baseline before starting therapy, as shown in Figure 4. The
development of useful biomarkers for the management of rheumatoid arthritis has been
extremely challenging. At present, there is no clinical parameter or laboratory test that can
distinguish likely responders to anti-TNF blockade prior to initiation of therapy. Given the
fact that at least 25% of patients will not respond to anti-TNF therapy, while at most one
third will have a robust clinical response, there is clearly a need to develop such markers.
Several small studies have proposed biomarkers to predict such response, but none have
been validated for any biologic therapy(16). It is important to note that published studies
suffer from reporting primary results and have not had multiple independent cohorts
available for validation and replication of results. A primary component of our work here is
replication of findings in multiple independent cohorts. In this context, our use of modular
approaches to whole blood microarray analysis identified suggestive feature sets for
prediction of response in individual cohorts but these marker sets failed to replicate or yield
a convincing gene expression biomarker for future drug response. This emphasizes the
biological complexity of the RA response phenotype. If the scientific community is to
succeed in the goal of response prediction, it is likely that multiple parameters will need to
be combined, including genetic and genomic data along with cellular and biochemical data
that more precisely reflect the underlying TNF dependence of the current inflammatory state
and inflammation drivers in a given patient.
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Our current results are likely to have utility in the context of determining the presence of
reduced disease activity in response to drug. This is an important issue, since the current
measures, such as the ACR and EULAR criteria, are highly dependent on primarily
subjective patient and physician based data points. The current results suggest that analysis
of modular gene expression can enhance the accuracy of a responder vs. non-responder
designation. For example, while the responder and non-responder groups show consistent
differences in the pattern of change in these modules, individuals may have a more or less
robust change. In the future we will generate an individually applicable “modular change
score”. A diagnostic biomarker of this type may be useful in assigning likelihood for
membership in the responder or non responder group, allow for decisions on change from
current therapy and to track the timing and durability of the response. As part of such an
effort we plan to incorporate other current measures of disease activity, such as the
proteomic panel described by the Vectra DA test(4, 22). Development of an improved RA
disease status scoring method will require careful exploration of combinations of modules
Arthritis Rheumatol. Author manuscript; available in PMC 2016 February 01.
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and other laboratory measures in order to optimize and validate such a method. Fortunately,
an additional validation dataset of over 100 additional subjects in the BATTERUP study will
shortly be available to permit a robust replication of the current findings as well as new
combinatorial approaches to individual categorization of response at a molecular level. Our
preliminary findings suggest that some patients who have a clinical response may not show
strong evidence of a biological response, possibly due to placebo effect. Likewise, subjects
with a biological response may exist within the “non-responder” group, again underlying
heterogeneity in the mechanisms of disease. Methods to better quantitatively classify
patients with regard to biological response will facilitate clinical treatment decisions and
enable the practice of “individualized medicine”(23) including such concepts as treat to
target(6). Finally, the outcome data and molecular interpretation presented in this manuscript
are restricted to anti-TNF treatment. In future studies it will be interesting to examine the
effect of alternative mechanisms of action on transcript modules.
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In addition to these considerations, the need for physician based data to categorize patient
response is a major barrier to carrying out large studies of biomarkers for drug response.
Without physician based data, studies of drug response, even when prospective, are
justifiably viewed with great skepticism. This means that any prospective study to
investigate potential new predictive biomarkers is logistically difficult and extremely
expensive. The current results suggest that it may be possible to combine changes in
modular gene expression, with solely patient based data to reach a convincing categorization
of drug response. If this can be achieved, it will dramatically enhance opportunities to
recruit large cohorts of patients starting new drugs without the traditional expenses
associated with physician led enrollment sites.
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Figure 1.

Summary of experimental approach and data analysis.
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Figure 2.

Summary of change in modules at 14 weeks compared with baseline in responders (R) and
non responders (NR) to anti-TNF therapy. The three cohorts -ABCoN (A), GO-FURTHER
(G) and BATTER-UP (B) - are indicated by the three sets of bars for each module. The
height of the bars shows the fraction of probes significantly changed (up or down) within
each module. Statistical significance of change is indicated by shading: black bars P<0.0005,
dark grey bars p<0.005, light grey bars p<0.05, open bars NS. Modules are designated
according to the original nomenclature in ref (17), with description accompanying selected
modules.
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Figure 3.

The distribution of significantly changed (p<0.05, see methods) probes within modules
between 14 weeks and baseline. The responders and responders are shown for each dataset:
panel A – ABCoN; panel B – GO_FURTHER; panel C – BATTERUP. The colors indicate
probes in modules with significant changes up (red) or down (blue), or no significant
modular changes (hypergeometric test, p<0.005). As noted in the text, many of these
modules exhibit changes with extremely high significance. For example p values for
modules module 2.5 range are 10-37, 10-82 and 10-68 in panels A, B and C respectively.
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Figure 4.

Comparison of module differences at baseline between responders and non-responders in all
three cohorts. Bar height indicates fraction of probes that are different between responders
and non responders, bar shading indicates significance of changes (see legend Figure 2).
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Clinical characteristics of patients in studied in the ABCoN, GO-FURTHER and BATTER-UP cohorts
Column1

ABCoN (n=50)

GO_FURTHER (n=72)

BATTER-UP (n=118)

AGE

55.62 sd 11.7

50.36 sd 10.91

53.3 sd 13.7

SEX F/M

39/11

53/19

96/22

CCP+and/orRF+

43 (86%)

72 (100%)

74 (62.7%)

DAS

5.24 sd .79

6.01 sd .84

5.12 sd 1.1

Good Responder

14

29

42

Moderate Responder

21

37

37

Non Responder

15

6

39

Infliximab

20

23

Enbrel

21

31
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Golimumab
Humira

72
9

9
41

Certolizumab Pegol

14

White

44

72

Black

2

13

Asian

2

2

Hispanic

2

7

Other

100

3

range

91-160

95-110

70-182

mean

103.4

99.3

105.1

SD

11.9

1.94

19.49
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